Telix Pharmaceuticals

Indianapolis,  IN 
United States
  • Booth: 239

Telix Pharmaceuticals Limited (Telix) is a commercial-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR). The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (JP) and Indianapolis (US). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer, with a recent FDA approval for a Gallium-based PSMA imaging agent.

For Technical Support with this webpage, please contact support.